Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC Injections for Oral Chronic GVHD
NCT02055625Phase 2Withdrawn
- Sponsor
- Karolinska Institutet
- Start
- Jan 2014
- Primary completion
- Aug 2019
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Provacel in graft-versus-host disease (GVHD), sponsored by Karolinska Institutet. Planned start Jan 2014; status: withdrawn.
02
Drugs
Provacel
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02055625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055625.